OLMA heads into a defining two-week stretch carrying its heaviest short interest in months, a freshly beaten Q1 print, and a key oncology conference on the horizon — all while the stock trades down 13% over the past month at $13.97.
The most striking development in OLMA's positioning is the rapid build in short interest over the past six weeks. Short interest as a percentage of free float has climbed from roughly 11.5% in early April to just under 19.4% now — a near-doubling in less than 45 days. That move is not noise. It reflects a deliberate, sustained increase in bearish positioning that accelerated sharply around April 23–24, when SI jumped from the mid-15s into the 19s almost overnight. The borrow market, by contrast, remains easy: availability is loose, and cost to borrow is close to historically low levels at 0.56% APR, down more than 26% over the past month. Short sellers are not paying a premium to maintain these positions — the borrow infrastructure is clearly there to support further accumulation if they choose to press.
Options positioning does not add much pressure to the bearish thesis. The put/call ratio is running near its 20-day average at 0.47, with a z-score barely above zero. There is no unusual surge in downside hedging from options traders. The PCR has drifted up from the low-0.26 range it occupied through most of April — a period when calls dominated — suggesting some modest rotation toward protection, but nothing that reads as a directional bet. On balance, the positioning picture is one where short sellers are clearly building, while options traders remain relatively neutral.
The Street is broadly bullish on OLMA but has been trimming targets steadily. The consensus remains Buy — Guggenheim reiterated that on May 13, within hours of the Q1 print — but the firm cut its target to $35 from $38, continuing a pattern of downward target drift that has been running since at least mid-March. At that point, Goldman Sachs lowered its target from $38 to $27, while JP Morgan moved the other direction, raising to $58. The mean consensus target across the coverage group is $42.63 against a current price of $13.97, an implied upside of more than 200%. That gap warrants caution: target dispersions in clinical-stage biotechs can be extreme and often lag clinical developments. Goldman's $27 target and Wolfe's neutral initiation (Peer Perform, no target) at end of March reflect the more sceptical end of the range.
The bull case rests on palazestrant's differentiated pharmacology as an oral SERD — specifically its pairing with ribociclib in the Phase 3 OPERA-02 study, which is generating genuine enthusiasm from academic KOLs. A positive readout from that trial could reframe OLMA as an acquisition target in the crowded ER+/HER2- breast cancer space. The bear case is simpler: OLMA is a single-asset story. The Q1 net loss widened to $53.1 million from $30.4 million a year ago, EPS came in at -$0.52, and while that beat the -$0.53 estimate by a penny, the losses are accelerating as the Phase 3 programme scales. The company also added a new board member with a deal-making background last week — notable context given the M&A speculation in the oral SERD sector.
Institutional ownership tells a supportive story. FMR (Fidelity) added nearly 5 million shares in the most recent reporting period to become the largest holder at 11.4% of shares outstanding. Artal Group — a specialist life sciences allocator — built a near-5-million share position, acquiring 3.9 million shares in the quarter to March. State Street added close to 2 million shares. These are large, directional adds from institutional names with biotech expertise, and they sit in notable contrast to the building short interest. That said, most insider activity in the data runs through January and early March 2026, when the stock was trading in the high-$20s — a period of net selling by the CFO, the founder/director, and the Chief Legal Officer. No insider buying is recorded at current prices.
The near-term calendar is what matters most. OLMA is confirmed to report a post-earnings event on May 15, providing further management commentary on the OPERA-02 timeline. The ASCO Annual Meeting in Chicago (May 28–June 2) is the next major potential data catalyst. Based on prior ORTEX earnings history, the stock fell 6.6% the day after its March 2026 event and was down a further 8.6% over five days. The November 2025 print was more muted at -1.9% on the day, though a subsequent five-day recovery of 2% followed. That asymmetry — two of three recent events ending in five-day losses — is worth watching as the ASCO window approaches and shorts continue to hold elevated positions.
See the live data behind this article on ORTEX.
Open OLMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
